Cingulate Inc. has made significant progress in addressing the U.S. Food and Drug Administration's (FDA) concerns regarding its new drug application (NDA) for CTx-1301. In a recent press release, Chairman and CEO Shane J. Schaffer discussed the company's ongoing efforts and anticipated timeline for resubmission, which is expected between December 2026 and January 2027.

This update is crucial for Cingulate as it navigates regulatory hurdles that could impact its product pipeline and market entry. The company aims to resubmit its NDA following the FDA's Complete Response Letter (CRL) issued on June 1, 2026, which requested additional chemistry, manufacturing, and controls (CMC) information. Notably, the CRL did not raise any concerns regarding the clinical safety or efficacy of CTx-1301.

Background

Cingulate Inc. operates within the pharmaceutical preparations sector, specifically focusing on developing innovative treatment options. The company, incorporated in Delaware, trades on the Nasdaq under the ticker symbols CING and CINGW. Its business address is located at 1901 W. 47th Place, Kansas City, KS 66205.

What the Filing Says

According to the SEC filing dated November 10, 2026, Cingulate's press release highlights the company's commitment to addressing the FDA's feedback. Schaffer stated, "We have substantially completed the manufacturing work required to address the CMC requests in the CRL and are finalizing the supporting data and documentation for a resubmission of the NDA." This proactive approach indicates Cingulate's readiness to comply with regulatory standards to move forward with its product.

Impact

The developments surrounding Cingulate's NDA resubmission are significant for various stakeholders, including investors, healthcare providers, and patients awaiting new treatment options. The pharmaceutical industry, particularly companies focused on similar therapeutic areas, will be closely monitoring Cingulate's progress as it could set a precedent for navigating FDA requirements.

What's Next

Looking ahead, Cingulate plans to submit the NDA resubmission by early 2027. The FDA is expected to classify the resubmission as either a Class 1 or Class 2, which would have review timelines of two months and six months, respectively. However, the filing does not specify any further actions or updates beyond the anticipated resubmission timeline.